Abstract
Background Drug reaction with eosinophilia and systemic symptoms (DRESS), a severe, delayed hypersensitivity reaction (DHR), is underrecognized, particularly in patients with inflammatory diseases. Atypical features arising during interleukin 1 (IL-1) and interleukin 6 (IL-6) inhibitor treatment of systemic onset juvenile arthritis (sJIA) and adult onset Stills disease (AOSD) suggested this serious DHR.
Methods We conducted a multi-center, retrospective study of a convenience sample of IL-1 or IL-6 inhibitor-exposed cases of sJIA, sJIA-like disease, AOSD, and Kawasaki disease (n=105 participants with sequence data or samples for HLA typing). Using pre-determined parameters, including RegiSCAR scoring for DRESS, subjects were classified as DHR-positive or drug-tolerant. HLA allele frequency was compared in cases versus drug-tolerant controls and versus the largest available sJIA cohort, collected by the International Childhood Arthritis Genetics Consortium (INCHARGE).
Results DHR features included eosinophilia (94%), AST-ALT elevation (70%), and non-evanescent rash (94%; 82% involving face). Cytokine storm syndrome during inhibitor treatment, a known complication of DRESS, was frequent (67%). A striking enrichment for common HLA-DRB1*15 haplotypes was present in DHR cases relative to drug-tolerant controls and was corroborated with the INCHARGE sJIA cohort (p=1×10−10). This association differs from the HLA-DR association with sJIA itself and is far stronger, as expected for HLA-associated DHR risk.
Conclusions Serious, at times fatal, DRESS-type reactions occur in a subset of patients exposed to IL-1/IL-6 inhibitors and strongly associate with HLA-DRB1*15 alleles that are common across ancestries. HLA testing before prescription warrants consideration, and alertness to DHR during treatment across conditions is prudent to improve safety.
Competing Interest Statement
VES reports personal fees from Novartis. GD reports personal fees from Novartis. SC reports personal fees from Novartis and grants from AB2 Bio. GS reports personal fees from Novartis. AAG reports grants and personal fees from Novartis and grants from NovImmune. SL reports personal fees from Novartis. SS reports personal fees from Novartis. MLS reports personal fees from Novartis. EDM reports grants from Novartis.
Funding Statement
Lucile Packard Foundation for Childrens Health, Stanford Maternal and Child Health Research Institute, National Institutes of Health and several private foundations. See appendix.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board, Stanford University. Local IRB approvals from contributing institutions were obtained as needed, based on local practice. Informed consent was obtained, as required. See appendix.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Drs. Hollenbach and Ombrello are equal contributors to this work, listed alphabetically.
↵** Drs. Mellins and Saper are co-senior and co-corresponding authors, listed alphabetically.
*** A list of members of the Consortium is provided in the Appendix.
This version includes more evidence for the development of drug hypersensitivity in the patients and importantly an increased number of cases and controls, which further support the HLA association reported in the initial description of this study. To accommodate the new information and include sufficient explanation of the various groups of subjects studied, this version is a full length paper.
Data Availability
All data referred to in the manuscript will be available upon reasonable request.
